Business
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
VANCOUVER, British Columbia & GRAPEVINE, Texas, February 25, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting.
About this update from Alpha Cognition Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1402,"height":504,"url":"https://media.zenfs.com/en/business-wire.com/58a0cad102f407d3105f2e5b3f9f8251"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OtiI7QtJN.8tBOtaS53b2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/58a0cad102f407d3105f2e5b3f9f8251","width":960,"height":345},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/12U5OKoAbCau5bvZ09yzWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/58a0cad102f407d3105f2e5b3f9f8251","width":1200,"height":431}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia & GRAPEVINE, Texas, February 25, 2026--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting.","length":494,"tagName":"p"},{"type":"text","content":"The BEACON study is designed to assess the real-world impact of ZUNVEYL on cognition, neuropsychiatric symptoms, safety, and tolerability in patients with Alzheimer’s disease residing in nursing homes. By generating data in routine clinical practice, the study aims to complement findings from earlier clinical trials and provide practice-relevant evidence in a care setting with significant unmet need that will further support the Company’s commercialization efforts.","length":469,"tagName":"p"},{"type":"text","content":""Enrollment of first patient in the BEACON study represents a significant milestone for Alpha Cognition," said Kurt Grady, Alpha Cognition’s Vice President of Medical Affairs. "This study is designed to generate real-world clinical evidence in the nursing home environment, where the need for effective and well-tolerated therapies is particularly high. If positive, these data have the potential to further strengthen the clinical foundation for ZUNVEYL and support our ongoing commercial launch by providing meaningful insights for he...